Altaris Capital Acquires Veranova (Johnson Matthey Health business)
June 1, 2022
Altaris Capital Partners completed the acquisition of Veranova (formerly Johnson Matthey's Health business) from Johnson Matthey PLC for total consideration of up to £325 million, with Johnson Matthey retaining approximately a 30% equity stake. Veranova is a global CDMO focused on specialty and complex active pharmaceutical ingredients (APIs), headquartered in Wayne, Pennsylvania, with roughly 900 employees across seven development and manufacturing sites in North America, Europe and Asia.
- Targets
- Veranova (formerly Johnson Matthey's Health business)
- Sellers
- Johnson Matthey PLC
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Arcline Investment Management to Acquire Novaria Group from KKR for $2.2 Billion
November 10, 2025
Industrial Services
Arcline Investment Management has entered into a definitive agreement to acquire Novaria Group for $2.2 billion. The deal will provide cash payouts to Novaria employees under the company’s employee ownership program and is expected to support Novaria’s continued expansion across the aerospace and defense supply chain.
-
Merck to Acquire Verona Pharma for Approximately $10 Billion
July 9, 2025
Pharmaceuticals
Merck, through a subsidiary, entered into a definitive agreement to acquire Verona Pharma in a transaction valued at approximately $10 billion (at $107 per ADS). The acquisition is intended to add Ohtuvayre (ensifentrine) to Merck’s cardio-pulmonary pipeline, following FDA approval for COPD in June 2024.
-
Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies
December 13, 2022
Medical Devices
Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.
-
Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer
December 30, 2021
Medical Devices
Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.
-
ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M
March 9, 2021
Pharmaceuticals
ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.
-
Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M
May 1, 2020
Medical Devices
Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.